Asset Details
Do you wish to reserve the book?
Structure and inhibition mechanism of the human citrate transporter NaCT
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Structure and inhibition mechanism of the human citrate transporter NaCT
Do you wish to request the book?
Structure and inhibition mechanism of the human citrate transporter NaCT
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Structure and inhibition mechanism of the human citrate transporter NaCT
2021
Overview
Citrate is best known as an intermediate in the tricarboxylic acid cycle of the cell. In addition to this essential role in energy metabolism, the tricarboxylate anion also acts as both a precursor and a regulator of fatty acid synthesis
1
–
3
. Thus, the rate of fatty acid synthesis correlates directly with the cytosolic concentration of citrate
4
,
5
. Liver cells import citrate through the sodium-dependent citrate transporter NaCT (encoded by
SLC13A5
) and, as a consequence, this protein is a potential target for anti-obesity drugs. Here, to understand the structural basis of its inhibition mechanism, we determined cryo-electron microscopy structures of human NaCT in complexes with citrate or a small-molecule inhibitor. These structures reveal how the inhibitor—which binds to the same site as citrate—arrests the transport cycle of NaCT. The NaCT–inhibitor structure also explains why the compound selectively inhibits NaCT over two homologous human dicarboxylate transporters, and suggests ways to further improve the affinity and selectivity. Finally, the NaCT structures provide a framework for understanding how various mutations abolish the transport activity of NaCT in the brain and thereby cause epilepsy associated with mutations in
SLC13A5
in newborns (which is known as SLC13A5-epilepsy)
6
–
8
.
Structures of the human sodium-dependent citrate transporter NaCT in complexes with citrate or a small-molecule inhibitor reveal how the inhibitor—which binds to the same site as citrate—arrests the transport cycle of NaCT.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 82/80
/ 82/83
/ Carrier Proteins - antagonists & inhibitors
/ Carrier Proteins - chemistry
/ Carrier Proteins - ultrastructure
/ Dicarboxylic Acid Transporters - chemistry
/ Dicarboxylic Acid Transporters - metabolism
/ Enzymes
/ Epilepsy
/ Homology
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ Neonates
/ Obesity
/ Phenylbutyrates - pharmacology
/ Proteins
/ Science
/ Substrate Specificity - drug effects
/ Substrate Specificity - genetics
